Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 800th surgery with the Episealer® knee implant. The reported implant revision rates remain low and presented clinical data is showing significant improvements for the Episealer® patients. About 340 patients have currently had the Episealer® implant for more than two years and about 50 patients for more than five years. Several scientific publications evaluating the technology are being prepared for publication.
“We are looking forward to reaching out to a larger group of surgeons and make the Episealer® technology available for more patients as additional clinical evidence is available from this group of patients” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
SOURCE: Episurf, 24th August 2020